Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 6/20 | 0.40 |
| ▸ | ESR2 | Q92731 | 6/20 | 0.40 |
| ▸ | CHRNB2 | P17787 | 4/20 | 0.35 |
| ▸ | CHRNA4 | P43681 | 4/20 | 0.35 |
| ▸ | CHRNB4 | P30926 | 2/20 | 0.35 |
| ▸ | CHRNA3 | P32297 | 2/20 | 0.35 |
| ▸ | CHRNA1 | P02708 | 1/20 | 0.33 |
| ▸ | CHRNG | P07510 | 1/20 | 0.33 |
| ▸ | CHRNB1 | P11230 | 1/20 | 0.33 |
| ▸ | CHRND | Q07001 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | KDM1A | O60341 | 1/20 | 0.32 |
| ▸ | RBP4 | P02753 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.31 |
| ▸ | KIF11 | P52732 | 1/20 | 0.31 |
| ▸ | HPGDS | O60760 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6396338 | 0.91 | ESR1 (0.40) | ESR1ESR2RBP4CYP2C19EPHX2 | |
| SCHEMBL4406850 | 0.84 | ESR1 (0.52) | ESR1ESR2CHRNB2CHRNA4CHRNB4 | |
| SCHEMBL31512129 | 0.83 | ESR1 (0.40) | ESR1ESR2CHRNB2CHRNA4CHRNB4 | |
| SCHEMBL3564889 | 0.83 | CHRNB2 (0.46) | ESR1ESR2CHRNB2CHRNA4CHRNB4 | |
| SCHEMBL4686593 | 0.83 | CHRNB2 (0.46) | ESR1ESR2CHRNB2CHRNA4RBP4 | |
| SCHEMBL29761239 | 0.83 | CHRNB2 (0.46) | ESR1ESR2CHRNB2CHRNA4CHRNB4 | |
| SCHEMBL13916013 | 0.82 | RBP4 (0.43) | ESR1ESR2KDM1ARBP4CYP2C19 | |
| SCHEMBL1971200 | 0.82 | RBP4 (0.43) | ESR1ESR2KDM1ARBP4CYP2C19 | |
| SCHEMBL4410052 | 0.81 | CHRNB2 (0.56) | ESR1ESR2CHRNB2CHRNA4CHRNB4 | |
| SCHEMBL16976391 | 0.81 | ESR1 (0.38) | ESR1ESR2CHRNB2CHRNA4CHRNB4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1044189-B2 | ARYL FUSED AZAPOLYCYCLIC COMPOUNDS | PFIZER PROD INC (US) | 2015-02-25 | — | — | EP | disclosed |
| EP-1619192-B1 | ARYL FUSED AZAPOLYCYCLIC COMPOUNDS | PFIZER PROD INC (US) | 2009-12-30 | — | — | EP | disclosed |
| EP-1383733-B1 | PROCESS FOR THE PREPARATION OF 1,3-SUBSTITUTED INDENES AND ARYL-FUSED AZAPOLYCYCLIC COMPOUNDS | PFIZER PROD INC (US) | 2008-03-05 | — | — | EP | disclosed |
| EP-1044189-B1 | ARYL FUSED AZAPOLYCYCLIC COMPOUNDS | PFIZER PROD INC (US) | 2008-02-13 | — | — | EP | disclosed |
| US-20070275973-A1 | ARYL FUSED AZAPOLYCYCLIC COMPOUNDS | PFIZER INC | 2007-11-29 | — | — | US | disclosed |
| US-7205300-B2 | Aryl fused azapolycyclic compounds | PFIZER INC (US) | 2007-04-17 | — | — | US | disclosed |
| US-7186870-B2 | Process for the preparation of 1,3-substituted indenes and aryl-fused azapolycyclic compounds | PFIZER INC (US) | 2007-03-06 | — | — | US | disclosed |
| US-7144882-B2 | Aryl fused azapolycyclic compounds | PFIZER INC (US) | 2006-12-05 | — | — | US | disclosed |
| US-7091372-B2 | Process for the preparation of 1,3-substituted indenes and aryl-fused azapolycyclic compounds | PFIZER INC (US) | 2006-08-15 | — | — | US | disclosed |
| EP-1259489-B1 | ARYL FUSED AZAPOLYCYCLIC COMPOUNDS | PFIZER PROD INC (US) | 2006-06-07 | — | — | EP | disclosed |
| US-6897310-B2 | Aryl fused azapolycyclic compounds | PFIZER INC (US) | 2005-05-24 | — | — | US | disclosed |
| US-6887884-B2 | Aryl fused azapolycyclic compounds | PFIZER INC (US) | 2005-05-03 | — | — | US | disclosed |
| US-6605610-B1 | Reducing nicotine addiction; treating neurological and psychological disorders | PFIZER INC | 2003-08-12 | — | — | US | disclosed |
| US-20030130260-A1 | Aryl fused azapolycyclic compounds | COE JOTHAM WADSWORTH (US) | 2003-07-10 | — | — | US | disclosed |
| US-20030060624-A1 | Process for the preparation of 1,3-substituted indenes and aryl-fused azapolycyclic componunds | PFIZER INC. | 2003-03-27 | — | — | US | disclosed |
| US-20020132824-A1 | Aryl fused azapolycyclic compounds | COE JOTHAM WADSWORTH (US) | 2002-09-19 | — | — | US | disclosed |
| US-20020111350-A1 | Aryl fused azapolycyclic compounds | COE JOTHAM WADSWORTH (US) | 2002-08-15 | — | — | US | disclosed |
| US-6410550-B1 | Aryl fused azapolycyclic compounds | PFIZER INC | 2002-06-25 | — | — | US | disclosed |
| US-20020072525-A1 | Aryl fused azapolycyclic compounds | PFIZER INC | 2002-06-13 | — | — | US | disclosed |
| US-20020072524-A1 | Aryl fused azapolycyclic compounds | WADSWORTH JOTHAM (US) | 2002-06-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020132824-A1 | Aryl fused azapolycyclic compounds | GRIN2C, GRIN2A, GRIN2B | ESR1 3094/4885ESR2 1196/4885CHRNB2 255/4885 |
| US-20030130260-A1 | Aryl fused azapolycyclic compounds | GRIN2C, GRIN2A, GRIN3A | ESR1 2825/4885ESR2 1314/4885CHRNB2 297/4885 |
| US-20020072524-A1 | Aryl fused azapolycyclic compounds | GRIN2C, GRIN2A, GRIN2B | ESR1 3094/4885ESR2 1196/4885CHRNB2 255/4885 |
| US-20020111350-A1 | Aryl fused azapolycyclic compounds | GRIN2C, GRIN2A, GRIN2B | ESR1 3094/4885ESR2 1196/4885CHRNB2 255/4885 |
| US-20070275973-A1 | ARYL FUSED AZAPOLYCYCLIC COMPOUNDS | GRIN2C, GRIN2A, GRIN2B | ESR1 1981/4885ESR2 1248/4885CHRNB2 221/4885 |
| US-20030060624-A1 | Process for the preparation of 1,3-substituted indenes and aryl-fused azapolycyclic componunds | INTS6, CYP1B1, CYP1A2 | ESR1 2089/4885ESR2 1087/4885CHRNB2 1306/4885 |
| US-20020072525-A1 | Aryl fused azapolycyclic compounds | GRIN2C, GRIN2A, GRIN2B | ESR1 3094/4885ESR2 1196/4885CHRNB2 255/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.